Innovative approaches to anti-arrhythmic drug therapy

被引:149
作者
Nattel, Stanley
Carlsson, Leif
机构
[1] Montreal Heart Inst, Dept Med, Montreal, PQ H1T 1C8, Canada
[2] Montreal Heart Inst, Res Ctr, Montreal, PQ H1T 1C8, Canada
[3] AstraZeneca Res & Dev, Integrat Pharmacol, S-43183 Molndal, Sweden
基金
加拿大健康研究院;
关键词
D O I
10.1038/nrd2112
中图分类号
Q81 [生物工程学(生物技术)]; Q93 [微生物学];
学科分类号
071005 ; 0836 ; 090102 ; 100705 ;
摘要
Normal cardiac function requires an appropriate and regular beating rate (cardiac rhythm). When the heart rhythm is too fast or too slow, cardiac function can be impaired, with derangements that vary from mild symptoms to life-threatening complications. Irregularities, particularly those involving excessively fast or slow rates, constitute cardiac 'arrhythmias'. In the past, drug treatment of cardiac arrhythmias has proven difficult, both because of inadequate effectiveness and a risk of serious complications. However, a variety of recent advances have opened up exciting possibilities for the development of novel and superior approaches to arrhythmia therapy. This article will review recent progress and future prospects for treating two particularly important cardiac arrhythmias: atrial fibrillation and ventricular fibrillation.
引用
收藏
页码:1034 / 1049
页数:16
相关论文
共 168 条
[1]   MiRP1 forms IKr potassium channels with HERG and is associated with cardiac arrhythmia [J].
Abbott, GW ;
Sesti, F ;
Splawski, I ;
Buck, ME ;
Lehmann, WH ;
Timothy, KW ;
Keating, MT ;
Goldstein, SAN .
CELL, 1999, 97 (02) :175-187
[2]   Ca2+/calmodulin-dependent protein kinase modulates cardiac ryanodine receptor phosphorylation and sarcoplasmic reticulum Ca2+ leak in heart failure [J].
Ai, X ;
Curran, JW ;
Shannon, TR ;
Bers, DM ;
Pogwizd, SM .
CIRCULATION RESEARCH, 2005, 97 (12) :1314-1322
[3]   Mechanisms underlying conduction slowing and arrhythmogenesis in nonischemic dilated cardiomyopathy [J].
Akar, FG ;
Spragg, DD ;
Tunin, RS ;
Kass, DA ;
Tomaselli, GF .
CIRCULATION RESEARCH, 2004, 95 (07) :717-725
[4]   Most LQT2 mutations reduce Kv11.1 (hERG) current by a class 2 (trafficking-deficient) mechanism [J].
Anderson, CL ;
Delisle, BP ;
Anson, BD ;
Kilby, JA ;
Will, ML ;
Tester, DJ ;
Gong, QM ;
Zhou, ZF ;
Ackerman, MJ ;
January, CT .
CIRCULATION, 2006, 113 (03) :365-373
[5]   We are not alone: Ion channel mutations in a long QT syndrome cohort [J].
Anderson, ME .
HEART RHYTHM, 2005, 2 (10) :1106-1107
[6]  
[Anonymous], 1989, NEW ENGL J MED, V321, P406
[7]   Brugada syndrome - Report of the second consensus conference [J].
Antzelevitch, C ;
Brugada, P ;
Borggrefe, M ;
Brugada, J ;
Brugada, R ;
Corrado, D ;
Gussak, I ;
LeMarec, H ;
Nademanee, K ;
Riera, ARP ;
Shimizu, W ;
Schulze-Bahr, E ;
Tan, H ;
Wilde, A .
HEART RHYTHM, 2005, 2 (04) :429-440
[8]   Brugada syndrome: From cell to bedside [J].
Antzelevitch, C ;
Brugada, P ;
Brugada, J ;
Brugada, R .
CURRENT PROBLEMS IN CARDIOLOGY, 2005, 30 (01) :9-54
[9]   STUDIES ON HEART .21. AMINO-ACID-SEQUENCE OF ANTIARRHYTHMIC PEPTIDE (AAP) ISOLATED FROM ATRIA [J].
AONUMA, S ;
KOHAMA, Y ;
MAKINO, T ;
FUJISAWA, Y .
JOURNAL OF PHARMACOBIO-DYNAMICS, 1982, 5 (01) :40-48
[10]  
AONUMA S, 1980, CHEM PHARM BULL, V28, P3332